MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of...
BMS
Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...
BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma
US-based Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another new indication approval in China for...
Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China...
Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...
Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
Baheal Partners with AstraZeneca for Commercial Rights to Onglyza
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...
Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...